| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-118 |
Sentence |
denotes |
Modeling new immunoregulatory therapeutics as antimicrobial alternatives for treating Clostridium difficile infection. |
| T1 |
0-118 |
Sentence |
denotes |
Modeling new immunoregulatory therapeutics as antimicrobial alternatives for treating Clostridium difficile infection. |
| T2 |
119-277 |
Sentence |
denotes |
The current treatment paradigm in Clostridium difficile infection is the administration of antibiotics contributing to the high rates of recurrent infections. |
| T2 |
119-277 |
Sentence |
denotes |
The current treatment paradigm in Clostridium difficile infection is the administration of antibiotics contributing to the high rates of recurrent infections. |
| T3 |
278-464 |
Sentence |
denotes |
Recent alternative strategies, such as fecal microbiome transplantation and anti-toxin antibodies, have shown similar efficacy in the treatment of C. difficile associated disease (CDAD). |
| T3 |
278-464 |
Sentence |
denotes |
Recent alternative strategies, such as fecal microbiome transplantation and anti-toxin antibodies, have shown similar efficacy in the treatment of C. difficile associated disease (CDAD). |
| T4 |
465-584 |
Sentence |
denotes |
However, barriers exist for either treatment or other novel treatments to displace antibiotics as the standard of care. |
| T4 |
465-584 |
Sentence |
denotes |
However, barriers exist for either treatment or other novel treatments to displace antibiotics as the standard of care. |
| T5 |
585-739 |
Sentence |
denotes |
To aid in the comparison of these and future treatments in CDAD, we developed an in silico pipeline to predict clinical efficacy with nonclinical results. |
| T5 |
585-739 |
Sentence |
denotes |
To aid in the comparison of these and future treatments in CDAD, we developed an in silico pipeline to predict clinical efficacy with nonclinical results. |
| T6 |
740-1146 |
Sentence |
denotes |
The pipeline combines an ordinary differential equation (ODE)-based model, describing the immunological and microbial interactions in the gastrointestinal (GI) mucosa, with machine learning algorithms to translate simulated output quantities (i.e. time of clearance, quantity of commensal bacteria, T cell ratios) into clinical predictions based on prior preclinical, translational and clinical trial data. |
| T6 |
740-1146 |
Sentence |
denotes |
The pipeline combines an ordinary differential equation (ODE)-based model, describing the immunological and microbial interactions in the gastrointestinal (GI) mucosa, with machine learning algorithms to translate simulated output quantities (i.e. time of clearance, quantity of commensal bacteria, T cell ratios) into clinical predictions based on prior preclinical, translational and clinical trial data. |
| T7 |
1147-1437 |
Sentence |
denotes |
As a use case, we compare the efficacy of lanthionine synthetase C-like 2 (LANCL2), a novel immunoregulatory target with promising efficacy in inflammatory bowel disease (IBD), activation with antibiotics, fecal microbiome transplantation and anti-toxin antibodies in the treatment of CDAD. |
| T7 |
1147-1437 |
Sentence |
denotes |
As a use case, we compare the efficacy of lanthionine synthetase C-like 2 (LANCL2), a novel immunoregulatory target with promising efficacy in inflammatory bowel disease (IBD), activation with antibiotics, fecal microbiome transplantation and anti-toxin antibodies in the treatment of CDAD. |
| T8 |
1438-1664 |
Sentence |
denotes |
We further validate the potential of LANCL2 pathway activation, in a mouse model of C. difficile infection in which it displays an ability to decrease weight loss and inflammatory cell types while protecting against mortality. |
| T8 |
1438-1664 |
Sentence |
denotes |
We further validate the potential of LANCL2 pathway activation, in a mouse model of C. difficile infection in which it displays an ability to decrease weight loss and inflammatory cell types while protecting against mortality. |
| T9 |
1665-1774 |
Sentence |
denotes |
The computational pipeline can serve as an important resource in the development of new treatment modalities. |
| T9 |
1665-1774 |
Sentence |
denotes |
The computational pipeline can serve as an important resource in the development of new treatment modalities. |